
    
      This study has two parts. Part A will be conducted in 72 healthy volunteers. Part B will be
      conducted in 20 patients diagnosed with COPD.

      Part A The primary objective of this part of the study is to assess the local tolerability of
      escalating doses of V0162 in male healthy volunteers.

      Part B The primary objective of this part of the study is to assess the bronchodilator
      properties of V0162 at the maximal tolerated dose (determined in Part A) in COPD patients.

      In addition, pharmacokinetics and vital sign including ECG will be determined.
    
  